PATENT CLAIM ANALYSIS

Application Number: 15747290
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "210200"]

Abstract:
The present disclosure features compounds such as those having the Formulae (I) and (II), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (I) or (II).

Claim (Index 18):
The method of any one of  claims 1 - 10 , wherein the patient has one copy of a F508del mutation and a second mutation that results in residual CFTR activity.

Metadata:
- Claim Count in Document: 167.0
- Percentile: 86.0
- Lexical Diversity: 1.63158
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15539392', '15320172', '15539405', '15766667', '15539397']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8263957760787662
- 35 USC 102 Novelty (BERT): 0.5513875148180497
- Combined Prediction Score: 0.7988949499526945
- Mean Citation Score: 418.138532
- Max Citation Score: 446.75592
- Similarity Product: 286.44203071174616

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test